Peritoneal carcinomatosis is a condition caused by advanced
stages of gynecological and gastrointestinal system cancers, as well as primary
peritoneal mesothelioma. 6-month survival can be achieved with palliative treatment in patients with
peritoneal carcinomatsis. Advances in cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy have made the curative approach for peritoneal carcinomatosis popular. The
main goal of cytoreductive surgery is to completely remove all tumor tissues, organs
and peritoneal surfaces without leaving visible tumor in the abdominal cavity.
Intraperitoneal chemotherapy administered after the operation aims to complete the microscopic
cytoreduction of tumor cells that are not visible macroscopically, with the effect of hot
chemotherapy, following cytoreduction. It is recommended to administer intraperitoneal chemotherapy at a
temperature of 40-42°C, where maximum chemosensitization is achieved. Cytoreductive
surgery and HIPEC enable a curative approach by increasing survival in these patient
groups with a poor natural course.
Bu kitabın bölümleri bulunmamaktadır.
Atıf Sayısı :
